Navigation Links
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:7/8/2009

SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of the shares are being offered by Arena. The gross proceeds to Arena, before expenses, from the sale of the shares are expected to be approximately $52.1 million. The closing of the offering is expected to take place on July 13, 2009. Piper Jaffray & Co. is acting as the sole underwriter in this offering.

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contacts:  Jack Lief
               President and CEO

               Robert E. Hoffman
               VP, Finance and CFO
               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 222

    www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals Announces Public Offering of Common Stock
2. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
3. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
4. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
5. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
6. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
7. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
9. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 2017 , ... A minimally invasive porcelain veneer is increasing ... Association of Dental Laboratories (NADL) is informing dentists about the benefits of minimally ... dental laboratories and technicians that create these veneers. , According to National ...
(Date:3/28/2017)... Kennett Square, PA (PRWEB) , ... March 28, 2017 , ... ... reputation online and across a variety of business channels. , While many results ... aspects of any public relations program. , When it comes to measurement, firms ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
Breaking Medicine Technology: